Replication-Competent AAV Vectors with RNAi Inhibitors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current AAV vectors lack sufficient production capacity and require helper viruses for replication, limiting their therapeutic potential due to their replication-incompetent nature and dependence on external helper functions.

Innovation Solution

Development of replication-competent AAV vectors equipped with an inhibitory expression cassette encoding RNAi molecules to target and inhibit helper viruses, enhancing their replication and antiviral efficacy while reducing dependence on external helper viruses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If AAV vectors are made replication-competent by including endogenous AAV genes, then production capacity and replication ability are improved, but the risk of helper virus interference and uncontrolled replication increases

Engineering Contradiction:

Improveproduction capacityVSAvoidsafety control

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent converts the harmful effect of helper viruses into a beneficial tool by using RNAi molecules that specifically target and inhibit helper virus genes. This allows the AAV vector to selectively suppress unwanted helper virus replication while maintaining its own replication capability through endogenous AAV genes, thus transforming a safety risk into a controlled mechanism for improving production capacity

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces RNAi molecules as intermediary agents that mediate between the replication-competent AAV vector and helper viruses. These RNAi molecules act as selective inhibitors that specifically target helper virus genes without affecting AAV vector replication, providing a controlled mechanism to manage the interaction between the vector and helper viruses while maintaining productivity

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of manufacture

If AAV vectors depend on external helper viruses for replication, then production is simplified, but therapeutic potential is limited due to replication-incompetent nature

Engineering Contradiction:

Improveproduction simplicityVSAvoidtherapeutic potential

Core Design Contradiction:

Ease of manufactureVSAdaptability or versatility

Solution Approach 1:

The patent enables AAV vectors to serve themselves by including endogenous AAV genes that provide replication functions previously dependent on external helper viruses. The vector now contains its own replication machinery, allowing it to replicate autonomously in target cells, thereby transforming from a replication-incompetent to a replication-competent system that maintains both manufacturing simplicity and enhanced therapeutic potential

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent segments the replication function from the helper virus dependency by incorporating specific endogenous AAV genes (such as rep and cap genes) into the vector construct. This segmentation allows the AAV vector to carry its own essential replication genes while leaving out other non-essential viral genes, creating a self-sufficient system that simplifies production and expands therapeutic applications

Inventive Principle:

Principle #1Segmentation

3Reliability

If RNAi molecules are used to inhibit helper virus genes, then antiviral efficacy is improved, but device complexity increases due to additional expression cassettes

Engineering Contradiction:

Improveantiviral efficacyVSAvoidvector structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges multiple functions into a single integrated AAV vector construct that simultaneously includes endogenous AAV genes for replication competence and RNAi expression cassettes for antiviral activity. By combining these elements into one unified vector system rather than separate components, the patent reduces overall system complexity while maintaining both replication capability and antiviral efficacy

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The replication-competent AAV vectors amplify and potentiate their antiviral effect, providing broader protection and increased production capacity, making them more effective against targeted helper viruses and safer for therapeutic use.

Implementation Method 1

an inhibitory expression cassette that includes a nucleotide sequence that encodes an RNAi molecule that inhibits expression of a targeted helper virus (THV) gene

Methodology Applied

Scientific EffectRNA interference (RNAi):

Data Source

PatentUS10370662B2Replication capable rAAV vectors encoding inhibitory siRNA and methods of their use

Publication Date: 2019.08.06 CITY OF HOPE

AI summary

In some embodiments, an antiviral vector is provided. The antiviral vector includes a replication competent adeno-associated virus (AAV) and an inhibitory expression cassette that includes a nucleotide sequence that encodes an RNAi molecule that inhibits expression of a targeted helper virus (THV) gene. The THV gene may be part of an Adenovirus (Ad) genome, a Human Papillomavirus (HPV) genome, a Human Herpes Virus (HHV) genome, or a Vaccinia virus (VV) genome.